News

Fungal Meningitis Outbreak Exposes Lack of Regulatory Oversight


 

The 23 states that received the implicated lots of medication are California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan, Minnesota, North Carolina, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, and West Virginia.

All reports of complaints or problems associated with these products should be made at the MedWatch website, the FDA’s voluntary reporting program, or by calling 800-FDA-1088.

Pages

Recommended Reading

Catching Drug Diverters
MDedge Rheumatology
Incorporate Nonpharmacologic Therapies for Fibromyalgia
MDedge Rheumatology
Prescription Drug Monitoring Programs Still Cumbersome
MDedge Rheumatology
Pitfalls in Prescribing for the Elderly
MDedge Rheumatology
Inappropriate Medications for the Elderly: Three Big Offenders
MDedge Rheumatology
Topical Pain Relievers: FDA Issues Burn Warning
MDedge Rheumatology
Prescription Drug Abuse Declines, Marijuana Use Still Common
MDedge Rheumatology
Chronic Musculoskeletal Pain Travels With Chronic Daily Headache
MDedge Rheumatology
Yoga, Tai Chi Underused in Rheumatic Pain Management
MDedge Rheumatology
Fungal Meningitis Cases, Deaths Continue to Rise
MDedge Rheumatology